Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H5U6

UPID:
ZCHC4_HUMAN

ALTERNATIVE NAMES:
Zinc finger CCHC domain-containing protein 4

ALTERNATIVE UPACC:
Q9H5U6; B2RXF6; B4DRD8; B7ZW20; Q5IW78; Q96AN7

BACKGROUND:
The enzyme rRNA N6-adenosine-methyltransferase ZCCHC4 specializes in the N6-methylation of adenine(4220) in 28S rRNA, a critical step required for translation. This methylation activity underscores the enzyme's essential role in the maintenance and efficiency of the protein synthesis machinery.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of rRNA N6-adenosine-methyltransferase ZCCHC4 offers a promising pathway towards identifying novel therapeutic approaches. Its central role in rRNA methylation positions it as a key target for the development of interventions aimed at modulating protein synthesis.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.